Pharma Focus Asia

WestVac Biopharma Receives Emergency Use Authorisation (EUA) for Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Vaccine

Friday, June 09, 2023

WestVac Biopharma has announced that the Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 vaccine is being approved for Emergency Use Authorisation (EUA) by relevant authorities in China.

Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 vaccine is the first in the world to receive Emergency Use Authorisation (EUA) against XBB descendent lineages of SARS-CoV-2. This vaccine offers a unique option for COVID-19 prevention by providing additional options for prevention and contributing to the ongoing management of the disease.

Coviccine® Trivalent XBB.1.5 is a promising broad-spectrum COVID-19 vaccine that induces a strong immune response, generates high levels of neutralising antibodies, and demonstrates a high protective efficacy against multiple prevalent subvariants.

The subunit vaccine antigen is designed based on the structure of the targeting S-RBD (spike receptor-binding domain) and HR (heptad repeat) proteins of the COVID-19 subvariants XBB.1.5 and BA.5.

Coviccine® Trivalent XBB.1.5 has shown promising results in terms of inducing a high titre of neutralising antibodies against multiple subvariants of the COVID-19 virus, including XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, and BA.2.75. This suggests that the vaccine may provide protection against a broad range of prevalent subvariants, both locally and internationally.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024